NCT05110053 (STEP-PD) is a NA clinical trial of Spinal Cord Stimulation in Parkinson Disease, sponsored by University of Aarhus.

Who is sponsoring NCT05110053?

NCT05110053 is sponsored by University of Aarhus.

What drugs are being tested in NCT05110053?

Interventions in NCT05110053: Spinal Cord Stimulation.

What condition does NCT05110053 study?

NCT05110053 studies Parkinson Disease, Gait Disorders, Neurologic, Fall Injury.

Is NCT05110053 still recruiting?

NCT05110053 is currently completed. Last updated 23 May 2025.

Last reviewed 2025-05-23 · How we verify

NCT05110053: STEP-PD

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Spinal Cord sTimulation thEraPy for Parkinson's Disease Patients With Gait Problems

Completed NA Last updated 23 May 2025

What this trial tests

NA trial testing Spinal Cord Stimulation in Parkinson Disease in 12 participants. Completed in 1 June 2024.

Timeline

1 September 2021

Primary endpoint
1 October 2023

1 June 2024

Quick facts

Lead sponsor	University of Aarhus
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	12
Start date	1 September 2021
Primary completion	1 October 2023
Estimated completion	1 June 2024
Sites	1 location across Denmark

Drugs / interventions tested

Spinal Cord Stimulation

Conditions studied

Parkinson Disease — all drugs for Parkinson Disease →
Gait Disorders, Neurologic — all drugs for Gait Disorders, Neurologic →
Fall Injury — all drugs for Fall Injury →

Sponsor

University of Aarhus

Who can join

50 and older, any sex, with Parkinson Disease or Gait Disorders, Neurologic. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Gait difficulties are common in Parkinson's disease (PD) and cause significant disability. No treatment is available for these symptoms. Spinal Cord Stimulation (SCS) has been found to improve gait, including freezing of gait, in a small number of PD patients. The mechanism of action is unclear and some patients are nonresponders. With this double-blind placebo-controlled proof of concept and feasibility imaging study, we aim to shed light on the mechanism of action of SCS and collect data to inform development of a scientifically sound clinical trial protocol. We also hope to identify imaging biomarkers at baseline that could be predictive of a favourable or a negative outcome of SCS and improve patient selection. Patients will be assessed with clinical rating scales and gait evaluations at baseline and 6 and 12 months after SCS. They will also receive serial 18F-FDG and (\[18F\]FEOBV) PET scans to assess the effects of SCS on cortical/subcortical activity and brain cholinergic function

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Spinal Cord Stimulation

Trials testing the same drug.

NCT07211308 — Open and Closed Loop DTM SCS in Patients With PSPS Type 2: ENDLESS Study · not yet recruiting
NCT06531837 — Electroencephalographic Characteristics of Chronic Pain in Patients With Spinal Cord Injury · NA · not yet recruiting
NCT06272539 — Spinal Cord Stimulation Combined With Exercise in Persistent Spinal Pain Syndrome · NA · recruiting
NCT06176391 — SCS for Vasospastic Angina Vasospastic Angina Pectoris - a Prospective Study · NA · unknown
NCT05624814 — Psychological Evaluation After SCS Implantation · unknown

Other recruiting trials for Parkinson Disease

Currently open trials in the same condition.

NCT07399496 — Accelerated TMS for Apathy in PD · NA · recruiting
NCT07371338 — Phase 1 Clinical Trial to Evaluate the Safety, Efficacy, and Pharmacokinetics of IPS101A in Parkinson's Disease Patients · Phase 1 · recruiting
NCT07442370 — The Effect of Functional Rotational Exercises on Fall Risk and Mobility in Parkinson's Disease Patients · NA · recruiting
NCT06848205 — Percept Transitions in FOG and PD · NA · recruiting
NCT07432958 — A Study to Evaluate the Effectiveness of Two Doses of AP-472 as Adjunctive Therapy to Levodopa in Parkinson's Disease (P · Phase 2 · recruiting

Other University of Aarhus trials

Trials by the same sponsor.

NCT07209540 — European LUpuS Inception-Cohort Developing initiATivE · not yet recruiting
NCT07317401 — Investigating the Effects of Intermittent Hypoxia-Hyperoxia Treatment (IHHT) in People With Post-Viral Myalgic Encephalo · NA · not yet recruiting
NCT07531966 — Vascular Complications After Kidney Transplantation · recruiting
NCT07528339 — Prospective RegIstry for Oncologic Reirradiation (PRIOR-DK) · not yet recruiting
NCT07451028 — Effect of an Oral Neuromuscular Training Device on Dysphagia · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05110053 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by University of Aarhus
Last refreshed: 23 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05110053.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing